<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523300</url>
  </required_header>
  <id_info>
    <org_study_id>GC-AD-2015-07</org_study_id>
    <nct_id>NCT02523300</nct_id>
  </id_info>
  <brief_title>Glucocorticoid on the Prognosis of TEVAR</brief_title>
  <official_title>Prognostic Value of Single-dose Glucocorticoid After Endovascular Repair for Aortic Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the potential prognostic effect of glucocorticoid on the postoperative
      aorta-related adverse events after aortic dissections patients underwent thoracic
      endovascular aortic repair (TEVAR), glucocorticoid (30mg/kg) will be intravenously given
      within 2h after TEVAR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open, single-center, randomized controlled trial. Number of patients:
      240 patients will be included and undertaken TEVAR.About 120 patients will be given
      glucocorticoid within 2h after TEVAR as experimental group, and the other 120 patients will
      be given saline as control group.

      Follow-up: 1. aortic computed tomographic angiography (CTA) examination 6, 12 and 24 months
      after TEVAR; 2. telephone or clinical follow-up at 1, 2, 3, 6, 12 and 24 months.

      Primary outcome measure: aorta-related adverse events. Second outcome measure: 30-day
      mortality after TEVAR, success rate of endovascular repair, drug-related adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aorta-related adverse events</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day mortality after TEVAR</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of endovascular repair</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-related adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Aortic Dissection</condition>
  <arm_group>
    <arm_group_label>TEVAR+GC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients underwent TEVAR. Then glucocorticoids will be intravenously given after TEVAR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEVAR+Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients underwent TEVAR. Then saline will be given after TEVAR</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TEVAR</intervention_name>
    <description>The patients will be undertaken TEVAR</description>
    <arm_group_label>TEVAR+GC</arm_group_label>
    <arm_group_label>TEVAR+Vehicle</arm_group_label>
    <other_name>thoracic endovascular aortic repair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group</description>
    <arm_group_label>TEVAR+GC</arm_group_label>
    <other_name>methylprednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>The other 120 patients will be given saline as control group</description>
    <arm_group_label>TEVAR+Vehicle</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age from 18 to 80, male or unpregnant female;

          2. diagnosed as aortic dissection, excluding intramural hematoma and penetrating aortic
             ulcer;

          3. complicated aortic dissection with definite indications of TEVAR;

          4. voluntarily signed the informed consent form;

          5. good compliance with the instructions and cooperate with follow-up.

        Exclusion Criteria:

          1. no appropriate vessel approaches;

          2. patients with connective tissue diseases (such as Marfan syndrome);

          3. patients with endocrine disease,such as diabetes mellitus, or undergoing
             hormonotherapy;

          4. bad compliance with the instructions and follow-up;

          5. allergic to nitinol and contrast medium;

          6. estimated life expectancy is less than 24 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaiping Jing, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Vascular Surgery, Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Zhou, Doctor</last_name>
    <phone>86-21-31161669</phone>
    <email>zhoujian1-2@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Zhang, Doctor</last_name>
    <phone>86-21-31161670</phone>
    <email>heatstones@yeah.net</email>
  </overall_contact_backup>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zaiping JING</investigator_full_name>
    <investigator_title>Director of Vascular Surgery Department</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

